Favipiravir (5 mg)

ZZZZ_Status (Active, Disc) : Active

AA_Supplier Name : Biosensis

Alternative_Name (Other Names) :

6-Fluoro-3-hydroxypyrazine-2-carboxamide; CAS 259793-96-9; T-705

Antibody_Isotype
(Antibody only) :

Application_Details :

Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [

Background_Info : T-705 (Favipiravir) is a broad-spectrum antiviral molecule currently in late stage clinical development for the treatment of influenza virus infection. Although it is believed that T-705 potency is mediated by its ribofuranosyl triphosphate (T-705 RTP) metabolite that could be mutagenic, the exact molecular interaction with the polymerase of influenza A virus (IAVpol) has not been elucidated.

Clone_Name
(AB only, monoclonals) :

Datasheet_Link : https://www.biosensis.com/pdf_datasheet.php?products_id=1823

Description (Long Description) : 

Favipiravir (T-705) is a novel viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with IC50 

Expiry_Date : 

See storage conditions.

Format (Form) : 

Dry powder; Off-white powder

Immunogen (Antigen) :157.1 g/mol Molecular Formula: C5H4FN3O2

Kit_Components :

MSDS (File name) :https://www.biosensis.com/pdf_MSDS.php?products_id=1823